secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2026-05-13T00:39:53+00:00
Accession:  0001140361-26-020896
Event type: earnings
Sentiment:  positive
Materiality: 0.95
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris raises $320M, Q1 cash burn $28.7M; PARADIGM trial enrols in US
----------------------------------------------------------------------

- Net operating cash outflows of $28.7M for Q1 2026, funding PARADIGM Trial and manufacturing scale-up.
- R&D expenses $17.5M, driven by clinical trial costs, manufacturing process validation, and headcount expansion.
- Completed $320M capital raises in January 2026 to support PARADIGM Trial and global commercialization of DurAVR THV.
- Post quarter-end, US patient enrollment in the PARADIGM Trial commenced; CMS coverage determination supports reimbursement.
- Presented EMBARK Study and EFS data at CRT 2026 and Sydney Valves 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126020896/0001140361-26-020896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126020896/ef20072992_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-020896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer